Bioassay of XXXX for possible carcinogenicity.

@entity652 @entity308 @entity37990 @entity19 @entity5 @entity189 @entity35 @entity811 @entity703
A bioassay of technical-grade @entity37990 for possible carcinogenicity was conducted by administering the test chemical in the diet to Osborne-Mendel @entity35 and B6C3F1 @entity19 . Groups of 50 @entity35 of each sex were administered @entity37990 at one of two doses for 80 weeks, then observed for 30-31 weeks. Time-weighted average doses for both males and females were 5,063 or 10,126 ppm. Matched controls consisted of groups of 10 untreated @entity35 of each sex; pooled controls consisted of the matched-control groups combined with 55 untreated male or female @entity35 from similar bioassays of five other test chemicals. All surviving @entity35 were killed at 110-111 weeks. Groups of 50 @entity19 of each sex were administered @entity37990 at one of two doses for 80 weeks, then observed for 11-12 weeks. Time-weighted average doses for males were 2,688 or 5,375 ppm, and for females, 3,000 or 6,000 ppm. Matched controls consisted of groups of 10 untreated @entity19 of each sex; pooled controls consisted of the matched-control groups combined with 50 untreated male or female @entity19 from similar bioassays of five other test chemicals. All surviving @entity19 were killed at 91-92 weeks. Clinical signs that appeared with increasing frequency in dosed @entity35 included @entity811 and, from week 72 until termination of the study, bright-yellow urine. Since the dosed female @entity19 did not have @entity308 in mean body weights or decreased survival compared with the controls, they may have been able to tolerate a higher dose. In @entity35 , @entity652 and @entity703 occurred with a significant dose-related trend in both the males (P=0.030) and the females (P=0.007). These @entity5 also occurred at a higher incidence in the high-dose males (P=0.035) and the high-dose females (P=0.016) than in the corresponding controls (males: pooled controls 0/62, low-dose 3/46, high-dose 4/49; females: pooled controls 0/62, low-dose 1/48, high-dose 5/50). These @entity5 included both @entity652 and @entity189 which are considered to be histogenically related. Thus these findings are interpreted as sufficient evidence for the carcinogenicity of @entity37990 . In @entity19 , no @entity5 were found to occur at a greater incidence among dosed animals than among controls. It is concluded that under the conditions of this bioassay, technical-grade @entity37990 was carcinogenic to Osborne-Mendel @entity35 , producing @entity5 of the kidney. @entity37990 was not carcinogenic for B6C3F1 @entity19 .
